Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium Capital December 27, 2023 17:45 CET Regulatory Read more
Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function December 20, 2023 22:15 CET Regulatory Read more
Calliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO® December 11, 2023 15:15 CET Regulatory Read more
Calliditas announces additions to the management team December 1, 2023 09:00 CET Regulatory Read more
Calliditas Therapeutics’ nomination committee composition for the AGM 2024 October 23, 2023 15:00 CET Regulatory Read more
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy August 18, 2023 10:00 CET Regulatory Read more
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) May 30, 2023 16:00 CET Regulatory Read more
Notice of annual general meeting of Calliditas Therapeutics AB (publ) April 28, 2023 08:30 CET Regulatory Read more
Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon[®] in IgA Nephropathy March 12, 2023 18:30 CET Regulatory Read more
Number of shares and votes in Calliditas Therapeutics January 31, 2023 08:00 CET Regulatory Read more
